The clinical potential of mRNA was revealed with COVID-19 vaccines, but that was just the beginning. “Today, this Nobel prize–winning technology is being leveraged for many therapeutic applications, ...

With the validation of the SARS-CoV-2 mRNA vaccines on the global stage, mRNA vaccines and therapeutics are taking the front seat of many biopharma development pipelines. There is an ever-increasing ...

Developers of mRNA therapeutics face an increasingly complex landscape: rising expectations for potency and durability, ...

From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.

Vaccines to prevent SARS-CoV-2 infection were not the first attempt at utilizing the promise of mRNA in a therapeutic setting. From the discovery of mRNA in the 1960s, many scientists, clinicians, and ...

Learn from the MHRA about evolving CMC expectations, submission criteria, and initiatives for streamlining approval routes for mRNA platforms. Continuous processing: Optimizing efficiency & ...

From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...

LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a ...

Ottawa, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The global mRNA synthesis & manufacturing market size is calculated at USD 1.55 billion in 2024, grows to USD 1.58 billion in 2025, and is projected to hit ...

mRNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the ...

- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc.